The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma
Status:
Terminated
Trial end date:
2018-04-18
Target enrollment:
Participant gender:
Summary
The primary purpose of the study will be testing the dosing of temozolomide to find the
target dose that a person can tolerate. The other part of the study will be determining how
helpful it can be to CNS lymphoma patients by adding temozolomide to the "conditioning
regimen" prior to stem cell transplantation.
This research study is designed to test the investigational use of temozolomide as part of a
conditioning regimen prior to stem cell transplantation. This drug has not yet been approved
by the U.S. Food and Drug Administration (FDA) to be used in the setting of stem cell
transplantation in lymphomas of the brain (central nervous system or CNS) but it has been
studied and used before in transplantation with reasonable results.